Anti-tumor effect of trametinib in bladder cancer organoid and the underlying mechanism

References

• Kamat AM, Hahn NM, Efstathiou JA, Lerner SP, Malmström P-U, Choi W, Guo CC, Lotan Y, Kassouf W. Bladder cancer. The Lancet. 2016;388(10061):2796–2810. doi:10.1016/S0140-6736(16)30512-8.
   PubMed Web of Science ®Google Scholar
• Rentsch CA, Muller DC, Ruiz C, Bubendorf L. Comprehensive molecular characterization of urothelial bladder carcinoma: a step closer to clinical translation? Eur Urol. 2017;72(6):960–961. doi:10.1016/j.eururo.2017.06.022.
   PubMed Web of Science ®Google Scholar
• Lerner SP, Schoenberg M, Sternberg C. 2006. Textbook of bladder cancer. Oxon. UK: Taylor and Francis. doi:10.1201/9780367800130
   Google Scholar
• Elbadawy M, Usui T, Mori T, Tsunedomi R, Hazama S, Nabeta R, Uchide T, Fukushima R, Yoshida T, Shibutani M, et al. Establishment of a novel experimental model for muscle-invasive bladder cancer using a dog bladder cancer organoid culture. Cancer Sci. 2019;110(9):2806–2821. doi:10.1111/cas.14118.
   PubMed Web of Science ®Google Scholar
• Sebolt-Leopold JS. Development of anticancer drugs targeting the MAP kinase pathway. Oncogene. 2000;19(56):6594–6599. doi:10.1038/sj.onc.1204083.
   PubMed Web of Science ®Google Scholar
• Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 2007;26(22):3291–3310. doi:10.1038/sj.onc.1210422.
   PubMed Web of Science ®Google Scholar
• Porter AC, Vaillancourt RR. Tyrosine kinase receptor-activated signal transduction pathways which lead to oncogenesis. Oncogene. 1998;17(11):1343–1352. doi:10.1038/sj.onc.1202171.
   PubMed Web of Science ®Google Scholar
• Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A, Ye Q, Lobo JM, She Y, Osman I, et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature. 2006;439(7074):358–362. doi:10.1038/nature04304.
   PubMed Web of Science ®Google Scholar
• Gilmartin AG, Bleam MR, Groy A, Moss KG, Minthorn EA, Kulkarni SG, Rominger CM, Erskine S, Fisher KE, Yang J, et al. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clin Cancer Res: Off J Am Assoc Cancer Res. 2011;17(5):989–1000. doi:10.1158/1078-0432.CCR-10-2200.
   PubMed Web of Science ®Google Scholar
• Kelly RJ. Dabrafenib and trametinib for the treatment of non-small cell lung cancer. Expert Rev Anticancer Ther. 2018;18(11):1063–1068. doi:10.1080/14737140.2018.1521272.
   PubMed Web of Science ®Google Scholar
• Hoffner B, Benchich K. Trametinib: a targeted therapy in metastatic melanoma. J Ad Pract Oncol. 2018;9(7):741–745.
   PubMedGoogle Scholar
• Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, Wen PY, Zielinski C, Cabanillas ME, Urbanowitz G, et al. Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600–mutant anaplastic thyroid cancer. J Clin Oncol. 2018;36(1):7–13. doi:10.1200/JCO.2017.73.6785.
   PubMed Web of Science ®Google Scholar
• Usui T, Sakurai M, Umata K, Elbadawy M, Ohama T, Yamawaki H, Hazama S, Takenouchi H, Nakajima M, Tsunedomi R, et al. Hedgehog signals mediate anti-cancer drug resistance in three-dimensional primary colorectal cancer organoid culture. Int J Mol Sci. 2018;19(4):1098. doi:10.3390/ijms19041098.
   Web of Science ®Google Scholar
• Usui T, Sakurai M, Nishikawa S, Umata K, Nemoto Y, Haraguchi T, Itamoto K, Mizuno T, Noguchi S, Mori T, et al. Establishment of a dog primary prostate cancer organoid using the urine cancer stem cells. Cancer Sci. 2017;108(12):2383–2392. doi:10.1111/cas.13418.
   PubMed Web of Science ®Google Scholar
• Abugomaa A, Elbadawy M, Yamanaka M, Goto Y, Hayashi K, Mori T, Uchide T, Azakami D, Fukushima R, Yoshida T, et al. Establishment of 2.5D organoid culture model using 3D bladder cancer organoid culture. Sci Rep. 2020;10(1):9393. doi:10.1038/s41598-020-66229-w.
   PubMed Web of Science ®Google Scholar
• Dong L, Lin F, Wu W, Liu Y, Huang W. Verteporfin inhibits YAP-induced bladder cancer cell growth and invasion via Hippo signaling pathway. Int J Med Sci. 2018;15(6):645–652. doi:10.7150/ijms.23460.
   PubMed Web of Science ®Google Scholar
• Gaver RC, George AM, Duncan GF, Morris AD, Deeb G, Faulkner HC, Farmen R. The disposition of carboplatin in the beagle dog. Cancer Chemother Pharmacol. 1988;21(3):197–202. doi:10.1007/BF00262769.
   PubMed Web of Science ®Google Scholar
• Takeuchi A, Eto M, Shiota M, Tatsugami K, Yokomizo A, Kuroiwa K, Itsumi M, Naito S. Sunitinib enhances antitumor effects against chemotherapy-resistant bladder cancer through suppression of ERK1/2 phosphorylation. Int J Oncol. 2012;40(5):1691–1696. doi:10.3892/ijo.2012.1368.
   PubMed Web of Science ®Google Scholar
• Ciamporcero E, Shen H, Ramakrishnan S, Ku S Y, Chintala S, Shen L, Adelaiye R, Miles KM, Ullio C, Pizzimenti S, et al. YAP activation protects urothelial cell carcinoma from treatment-induced DNA damage. Oncogene. 2016;35(12):1541–1553. doi:10.1038/onc.2015.219.
   PubMed Web of Science ®Google Scholar
• Sjodahl G, Lauss M, Lovgren K, Chebil G, Gudjonsson S, Veerla S, Patschan O, Aine M, Fernö M, Ringnér M, et al. A molecular taxonomy for urothelial carcinoma. Clin Cancer Res: Off J Am Assoc Cancer Res. 2012;18(12):3377–3386. doi:10.1158/1078-0432.CCR-12-0077-T.
   PubMed Web of Science ®Google Scholar
• Choi W, Porten S, Kim S, Willis D, Plimack ER, Hoffman-Censits J, Roth B, Cheng T, Tran M, Lee I-L, et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell. 2014;25(2):152–165. doi:10.1016/j.ccr.2014.01.009.
   PubMed Web of Science ®Google Scholar
• Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F. Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol. 2017;71(1):96–108. doi:10.1016/j.eururo.2016.06.010.
   PubMed Web of Science ®Google Scholar
• Elbadawy M, Yamanaka M, Goto Y, Hayashi K, Tsunedomi R, Hazama S, Nagano H, Yoshida T, Shibutani M, Ichikawa R, et al. Efficacy of primary liver organoid culture from different stages of non-alcoholic steatohepatitis (NASH) mouse model. Biomaterials. 2020;237:119823. doi:10.1016/j.biomaterials.2020.119823.
   PubMed Web of Science ®Google Scholar
• Usui T, Sakurai M, Enjoji S, Kawasaki H, Umata K, Ohama T, Fujiwara N, Yabe R, Tsuji S, Yamawaki H, et al. Establishment of a novel model for anticancer drug resistance in three-dimensional primary culture of tumor microenvironment. Stem Cells Int. 2016;2016:7053872. doi:10.1155/2016/7053872.
   PubMed Web of Science ®Google Scholar
• Usui T, Elbadawy M, Sasaki K. Session 6: advances in anticancer therapy. J Vet Pharmacol Ther. 2018;41:28–30. doi:10.1111/jvp.12625
   PubMedGoogle Scholar
• Elbadawy M, Usui T, Yamawaki H, Sasaki K. Development of an experimental model for analyzing drug resistance in colorectal cancer. Cancers (Basel). 2018;10(6):164. doi:10.3390/cancers10060164.
   Web of Science ®Google Scholar
• Abugomaa A, Elbadawy M. Patient-derived organoid analysis of drug resistance in precision medicine: is there a value? Expert Rev Precis Med Drug Dev. 2020;5(1):1–5. doi:10.1080/23808993.2020.1715794.
   Web of Science ®Google Scholar
• Elbadawy M, Abugomaa A, Yamawaki H, Usui T, Sasaki K. Development of prostate cancer organoid culture models in basic medicine and translational research. Cancers (Basel). 2020;12(4):777. doi:10.3390/cancers12040777.
   Web of Science ®Google Scholar
• Prasad SM, Decastro GJ, Steinberg GD. Medscape. Urothelial carcinoma of the bladder: definition, treatment and future efforts. Nat Rev Urol. 2011;8(11):631–642. doi:10.1038/nrurol.2011.144.
   PubMed Web of Science ®Google Scholar
• Su H, Jiang H, Tao T, Kang X, Zhang X, Kang D, Li S, Li C, Wang H, Yang Z, et al. Hope and challenge: precision medicine in bladder cancer. Cancer Med. 2019;8(4):1806–1816. doi:10.1002/cam4.1979.
   PubMed Web of Science ®Google Scholar
• Pinto-Leite R, Arantes-Rodrigues R, Sousa N, Oliveira PA, Santos L. mTOR inhibitors in urinary bladder cancer. Tumour Biol: J Int Soc Oncodev Biol Med. 2016;37(9):11541–11551. doi:10.1007/s13277-016-5083-1.
   PubMedGoogle Scholar
• Sakai K, Maeda S, Saeki K, Nakagawa T, Murakami M, Endo Y, Yonezawa T, Kadosawa T, Mori T, Nishimura R, et al. Anti-tumour effect of lapatinib in canine transitional cell carcinoma cell lines. Vet Comp Oncol. 2018;16(4):642–649. doi:10.1111/vco.12434.
   PubMed Web of Science ®Google Scholar
• Tsai YC, Ho PY, Tzen KY, Tuan TF, Liu WL, Cheng AL, Pu YS, Cheng JC-H, Synergistic blockade of EGFR and HER2 by new-generation EGFR tyrosine kinase inhibitor enhances radiation effect in bladder cancer cells. Mol Cancer Ther. 2015;14(3):810–20. doi:10.1158/1535-7163.MCT-13-0951
   Google Scholar
• Hanazono K, Fukumoto S, Kawamura Y, Endo Y, Kadosawa T, Iwano H, Uchide T. Epidermal growth factor receptor expression in canine transitional cell carcinoma. J Vet Med Sci. 2015;77(1):1–6. doi:10.1292/jvms.14-0032.
   PubMed Web of Science ®Google Scholar
• Cohen P. Protein kinases — the major drug targets of the twenty-first century? Nat Rev Drug Discov. 2002;1(4):309–315. doi:10.1038/nrd773.
   PubMed Web of Science ®Google Scholar
• Kawahara T, Ide H, Kashiwagi E, Patterson JD, Inoue S, Shareef HK, Aljarah AK, Zheng Y, Baras AS, Miyamoto H, et al. 2015. Silodosin inhibits the growth of bladder cancer cells and enhances the cytotoxic activity of cisplatin via ELK1 inactivation. Am J Cancer Res. 5(10):2959–2968.
   PubMed Web of Science ®Google Scholar
• Huang C, Liu J, Xu L, Hu W, Wang J, Wang M, Yao X. MicroRNA-17 promotes cell proliferation and migration in human colorectal cancer by downregulating SIK1. Cancer Manag Res. 2019;11:3521–3534. doi:10.2147/CMAR.S191087.
   PubMed Web of Science ®Google Scholar
• Huang S, Xue P, Han X, Zhang C, Yang L, Liu L, Wang X, Li H, Fu J, Zhou Y, et al. Exosomal miR-130b-3p targets SIK1 to inhibit medulloblastoma tumorigenesis. Cell Death Dis. 2020;11(6):408. doi:10.1038/s41419-020-2621-y.
   PubMed Web of Science ®Google Scholar
• Hollstein PE, Eichner LJ, Brun SN, Kamireddy A, Svensson RU, Vera LI, Ross DS, Rymoff TJ, Hutchins A, Galvez HM, et al. The AMPK-related kinases SIK1 and SIK3 mediate key tumor-suppressive effects of LKB1 in NSCLC. Cancer Discov. 2019;9(11):1606–1627. doi:10.1158/2159-8290.CD-18-1261.
   PubMed Web of Science ®Google Scholar
• Abugomaa A, Elbadawy M, Yamawaki H, Usui T, Sasaki K. Emerging roles of cancer stem cells in bladder cancer progression, tumorigenesis, and resistance to chemotherapy: a potential therapeutic target for bladder cancer. Cells. 2020;9(1):235. doi:10.3390/cells9010235.
   Web of Science ®Google Scholar
• Brandt WD, Matsui W, Rosenberg JE, He X, Ling S, Schaeffer EM, Berman DM. Urothelial carcinoma: stem cells on the edge. Cancer Metastasis Rev. 2009;28(3–4):291–304. doi:10.1007/s10555-009-9187-6.
   PubMed Web of Science ®Google Scholar
• Naor D, Sionov RV, Ish-Shalom D. CD44: structure, function, and association with the malignant process. Adv Cancer Res. 1997;71:241–319.
   PubMed Web of Science ®Google Scholar
• Maehara O, Suda G, Natsuizaka M, Ohnishi S, Komatsu Y, Sato F, Nakai M, Sho T, Morikawa K, Ogawa K, et al. Fibroblast growth factor-2-mediated FGFR/Erk signaling supports maintenance of cancer stem-like cells in esophageal squamous cell carcinoma. Carcinogenesis. 2017;38(11):1073–1083. doi:10.1093/carcin/bgx095.
   PubMed Web of Science ®Google Scholar
• Cho H, Matsumoto S, Fujita Y, Kuroda A, Menju T, Sonobe M, Kondo N, Torii I, Nakano T, Lara PN, et al. Trametinib plus 4-methylumbelliferone exhibits antitumor effects by ERK blockade and CD44 downregulation and affects PD-1 and PD-L1 in malignant pleural mesothelioma. J Thorac Oncol: Off Publ Int Assoc Study Lung Cancer. 2017;12(3):477–490. doi:10.1016/j.jtho.2016.10.023.
   Google Scholar
• Beverdam A, Claxton C, Zhang X, James G, Harvey KF, Key B. Yap controls stem/progenitor cell proliferation in the mouse postnatal epidermis. J Invest Dermatol. 2013;133(6):1497–1505. doi:10.1038/jid.2012.430.
   PubMed Web of Science ®Google Scholar
• Johnson R, Halder G. The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment. Nat Rev Drug Discov. 2014;13(1):63–79. doi:10.1038/nrd4161.
   PubMed Web of Science ®Google Scholar
• Ooki A, Del Carmen Rodriguez Pena M, Marchionni L, Dinalankara W, Begum A, Hahn NM, VandenBussche CJ, Rasheed ZA, Mao S, Netto GJ, et al. YAP1 and COX2 coordinately regulate urothelial cancer stem-like cells. Cancer Res. 2018;78(1):168–181. doi:10.1158/0008-5472.CAN-17-0836.
   PubMed Web of Science ®Google Scholar
• Liu JY, Li YH, Lin HX, Liao YJ, Mai SJ, Liu ZW, Zhang Z-L, Jiang L-J, Zhang J-X, Kung H-F, et al. Overexpression of YAP 1 contributes to progressive features and poor prognosis of human urothelial carcinoma of the bladder. BMC Cancer. 2013;13(1):349. doi:10.1186/1471-2407-13-349.
   PubMed Web of Science ®Google Scholar
• Kandasamy S, Adhikary G, Rorke EA, Friedberg JS, Mickle MB, Alexander HR, Eckert RL. The YAP1 signaling inhibitors, verteporfin and CA3, suppress the mesothelioma cancer stem cell phenotype. Mol Cancer Res: MCR. 2020;18(3):343–351. doi:10.1158/1541-7786.MCR-19-0914.
   PubMed Web of Science ®Google Scholar
• Jiang N, Hjorth-Jensen K, Hekmat O, Iglesias-Gato D, Kruse T, Wang C, Wei W, Ke B, Yan B, Niu Y, et al. In vivo quantitative phosphoproteomic profiling identifies novel regulators of castration-resistant prostate cancer growth. Oncogene. 2015;34(21):2764–2776. doi:10.1038/onc.2014.206.
   PubMed Web of Science ®Google Scholar
• Feng X, Degese MS, Iglesias-Bartolome R, Vaque JP, Molinolo AA, Rodrigues M, Zaidi M, Ksander B, Merlino G, Sodhi A, et al. Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry. Cancer Cell. 2014;25(6):831–845. doi:10.1016/j.ccr.2014.04.016.
   PubMed Web of Science ®Google Scholar
• Choi W, Czerniak B, Ochoa A, Su X, Siefker-Radtke A, Dinney C, McConkey DJ. Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer. Nat Rev Urol. 2014;11(7):400–410. doi:10.1038/nrurol.2014.129.
   PubMed Web of Science ®Google Scholar
• Volkmer JP, Sahoo D, Chin RK, Ho PL, Tang C, Kurtova AV, Willingham SB, Pazhanisamy SK, Contreras-Trujillo H, Storm TA, et al. Three differentiation states risk-stratify bladder cancer into distinct subtypes. Proc Natl Acad Sci U S A. 2012;109(6):2078–2083. doi:10.1073/pnas.1120605109.
   PubMed Web of Science ®Google Scholar
• Hurst CD, Knowles MA. Molecular subtyping of invasive bladder cancer: time to divide and rule? Cancer Cell. 2014;25(2):135–136. doi:10.1016/j.ccr.2014.01.026.
   PubMed Web of Science ®Google Scholar
• Bayat Mokhtari R, Homayouni TS, Baluch N, Morgatskaya E, Kumar S, Das B, Yeger H. Combination therapy in combating cancer. Oncotarget. 2017;8(23):38022–38043. doi:10.18632/oncotarget.16723.
   PubMed Web of Science ®Google Scholar
• Goodspeed A, Jean A, Costello JC. A whole-genome CRISPR screen identifies a role of MSH2 in cisplatin-mediated cell death in muscle-invasive bladder cancer. Eur Urol. 2019;75(2):242–250. doi:10.1016/j.eururo.2018.10.040.
   PubMed Web of Science ®Google Scholar
• Mucaki EJ, Zhao JZL, Lizotte DJ, Rogan PK. Predicting responses to platin chemotherapy agents with biochemically-inspired machine learning. Signal Transduction Targeted Ther. 2019;4(1):1. doi:10.1038/s41392-018-0034-5.
   PubMedGoogle Scholar
• Ting S, Mairinger FD, Hager T, Welter S, Eberhardt WE, Wohlschlaeger J, Schmid KW, Christoph DC. ERCC1, MLH1, MSH2, MSH6, and betaIII-tubulin: resistance proteins associated with response and outcome to platinum-based chemotherapy in malignant pleural mesothelioma. Clin Lung Cancer. 2013;14(5):558–67 e3. doi:10.1016/j.cllc.2013.04.013.
   PubMed Web of Science ®Google Scholar
• Gong JG, Costanzo A, Yang HQ, Melino G, Kaelin WG Jr., Levrero M, Wang JYJ. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature. 1999;399(6738):806–809. doi:10.1038/21690.
   PubMed Web of Science ®Google Scholar
• Brown R, Hirst GL, Gallagher WM, McIlwrath AJ, Margison GP, Van Der Zee AG, Anthoney DA. hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents. Oncogene. 1997;15(1):45–52. doi:10.1038/sj.onc.1201167.
   PubMed Web of Science ®Google Scholar
• Liang JY, Yang QF, Zeng YL, Liu YY, Liu YT, Gu FF, Hu Y, Zhang K, Zhong H, Liu L, et al. Clinical value of MLH1-negative circulating tumor cells in lung cancer patients. Med (Baltimore). 2019;98(25):e15721. doi:10.1097/MD.0000000000015721.
   PubMed Web of Science ®Google Scholar
• Xie KJ, He HE, Sun AJ, Liu XB, Sun LP, Dong XJ. Expression of ERCC1, MSH2 and PARP1 in non-small cell lung cancer and prognostic value in patients treated with platinum-based chemotherapy. Asian Pac J Cancer Prev. 2014;15(6):2591–2596. doi:10.7314/APJCP.2014.15.6.2591.
   PubMedGoogle Scholar
• Chun R, Knapp DW, Widmer WR, DeNicola DB, Glickman NW, Kuczek T, Degortari A, Han CM. Phase II clinical trial of carboplatin in canine transitional cell carcinoma of the urinary bladder. J Vet Intern Med. 1997;11(5):279–283. doi:10.1111/j.1939-1676.1997.tb00465.x.
   PubMed Web of Science ®Google Scholar
• Allstadt SD, Rodriguez CO Jr., Boostrom B, Rebhun RB, Skorupski KA. Randomized phase III trial of piroxicam in combination with mitoxantrone or carboplatin for first-line treatment of urogenital tract transitional cell carcinoma in dogs. J Vet Intern Med. 2015;29(1):261–267. doi:10.1111/jvim.12533.
   PubMed Web of Science ®Google Scholar
• Hudson E, Lester JF. Gemcitabine and carboplatin in the treatment of transitional cell carcinoma of the urothelium: a single centre experience and review of the literature. Eur J Cancer Care (Engl). 2010;19(3):324–328. doi:10.1111/j.1365-2354.2008.01050.x.
   PubMed Web of Science ®Google Scholar
• Lin SH, Mok I, Leos D, Pasia MG, Thall PF, Lin HY, Welliver MX, Villalona-Calero MA, Yao JC, Meric-Bernstam F, et al. NCI 9448: phase I study of trametinib in combination with chemoradiation for KRAS-mutant non-small cell lung cancer. J Clin Oncol. 2015;33(15_suppl): TPS7585–TPS. doi:10.1200/jco.2015.33.15_suppl.tps7585.
   Web of Science ®Google Scholar